Clinical trial
Efficacy and Safety of Immunomodulator as an Adjunct Therapy in New Pulmonary…
NCT00341328 · Ministry of Science and Technology, India, Other · Completed
Key facts
| NCT number | NCT00341328 |
|---|---|
| Title | Efficacy and Safety of Immunomodulator as an Adjunct Therapy in New Pulmonary Tuberculosis(Category I) Patients. |
| Official title | Efficacy and Safety of Immunomodulator (Mycobacterium w.) as an Adjunct Therapy in Category I Pulmonary Tuberculosis and Along With Assessment of Immunological Parameters |
| Lead sponsor | Ministry of Science and Technology, India, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Tuberculosis |
| Intervention type | Biological |
| Interventions | Intradermal injection of Mycobacterium w |
| Enrollment | 300 |
| Start date | Mar 1, 2007 |
| Primary completion | Oct 1, 2011 |
| Completion | Mar 1, 2012 |
| First posted | Jun 21, 2006 |
| Last update posted | Apr 26, 2013 |
| Countries | India |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: